Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
December 19 2013 - 9:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded multicellular therapies for the treatment
of severe chronic cardiovascular diseases, today announced that it
has been granted a key composition-of-matter patent from the
Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy
product candidate.
The issued patient, entitled "Mixed Cell Populations for Tissue
Repair and Separation Technique for Cell Processing," provides
protection for key characteristics of ixmyelocel-T through 2027.
Aastrom now holds patent protection for ixmyelocel-T in Australia,
the United States and the European Union.
"Patent approval in Australia expands our opportunity to
commercialize ixmyelocel-T in multiple therapeutic markets and
consider a range of partnership opportunities and other strategies
to advance ixmyelocel-T through clinical development," said Nick
Colangelo, president and chief executive officer at Aastrom
Biosciences.
Aastrom is currently conducting the Phase 2b ixCELL-DCM clinical
study of ixmyelocel-T in the United States and Canada for the
treatment of advanced heart failure due to ischemic dilated
cardiomyopathy, a progressive disease of heart muscle and a leading
cause of heart failure and heart transplantation.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular diseases.
The company's proprietary cell-processing technology enables the
manufacture of ixmyelocel-T, a patient-specific multicellular
therapy expanded from a patient's own bone marrow and delivered
directly to damaged tissues. Aastrom has advanced ixmyelocel-T into
late-stage clinical development, including a Phase 2b clinical
trial in patients with advanced heart failure due to ischemic
dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with the
closing of the offering described herein, Aastrom's intended use of
proceeds in connection with the offering, clinical trial and
product development activities, regulatory approval requirements,
competitive developments, and the availability of resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Registration Statement on Form S-1 described above,
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. These
forward-looking statements reflect management's current views and
Aastrom does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date of this release except as
required by law.
CONTACT: Media contact:
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024